Regeneron Pharmaceuticals (NasdaqGS:REGN) recently presented positive results from its Dupixent trial for bullous pemphigoid at the AAD Annual Meeting, demonstrating its ongoing strides in addressing ...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...

Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.

The table is a review of notable updates that occurred in February 2025 for investigational products in development.

Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Unusual Physical Finding in 2 Vietnamese Girls Healthcare providers must understand the rationale for traditional treatments practiced by ethnic groups so that resultant physical findings can can ...

Bullous pemphigoid is an autoimmune skin disease characterized by tense blisters and erosions. In this Primer, Akbarialiabad et al. review the epidemiology, pathophysiology, diagnosis and ...

As of 3:33:23 PM EDT. Market Open. Loading Chart for ARGX ...